Overview

TMC114-TiDP29-C169: Bioavailability and Pharmacokinetics Trial Comparing Darunavir Pediatric Suspension Formulation to Current Darunavir Tablet

Status:
Completed

Trial end date:
2008-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate in healthy volunteers how much and how fast the new suspension compared to the commercial darunavir tablet, given in combination with low-dose ritonavir, are absorbed into the body (called the relative oral bioavailability).

Phase:

Phase 1

Details

Lead Sponsor:

Tibotec Pharmaceuticals, Ireland

Treatments:

Darunavir